Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? A case report;Czy każdy przypadek uszkodzenia miȩśni w przebiegu terapii hipolipemizuja̧cej jest jej działaniem niepoża̧ danym? Opis przypadku

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue 10, 2007, Pages 473-476

  Kȩdzia, Agnieszka ^a   Krysiak, Robert ^a   Madej, Andrzej ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Creatine phosphokinase; Fibrates; Hypothyroidism; Myopathy; Statins

Indexed keywords

ANTILIPEMIC AGENT; CREATINE KINASE; THYROID HORMONE;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ENZYME ACTIVITY; HUMAN; LABORATORY TEST; MALE; MYOPATHY; REMISSION; THYROID DISEASE; BLOOD; CHEMICALLY INDUCED DISORDER; HYPOTHYROIDISM; MIDDLE AGED; MUSCLE DISEASE; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; CREATINE KINASE; HUMANS; HYPOTHYROIDISM; MALE; MIDDLE AGED; MUSCULAR DISEASES; THYROID HORMONES; TREATMENT OUTCOME;

EID: 38049067507     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Oh J, Ban MR, Miskie BA, et al. Genetic determinants of statin intolerance. Lipids Health Dis. 2007; 21: 6-7.
2. De Bleecker JL. How to approach the patient with muscular symptoms in the general neurological practice? Acta Neurol Belg. 2005; 105: 18-22.
3. Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Eur J Intern Med. 2007; 18: 90-100.
4. Lang J, Wang P, Glueck C. Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism. Clin Chim Acta. 1996; 254: 65-92.
5. Finsterer J. Fibrat/Statin - Myopathie. Nervenarzt. 2003; 74: 115-122.
6. Shek A, Ferill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001; 35: 908-917.
7. Schech S, Graham D, Staffa J, et al. Risk factors for statin - associated rhabdomyolisis. Pharmacoepidemiol Drug Saf. 2007; 16: 352-358.
8. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI Advisory on the use and safety of statins. Circulation. 2002; 106: 1024-1028.
9. Lin RT, Liu CK, Tai CT, et al. Hypothyroid myopathy - pathological and ultrastructural study. Kaohsiung J Med Sci. 2000; 16: 68-75.
10. Prudhomme F, Jacotot B. Muscular toxicity of antilipemic agents revealed during the course of hypothyroidism. Presse Med. 2003; 32: 1031-1032.
11. Łukjanowicz M, Trzcińska-Butkiewicz B, Brzosko M. Miopatia spowodowana stosowaniem fenofibratu u osoby z nierozpoznana̧ niedoczynnościa̧ tarczycy - opis przypadku i przegla̧d piśmiennictwa. Pol Arch Med Wewn. 2006; 115: 45-49.
12. Klein I, Parker M, Shebert R, et al. Hypothyroidism presenting as muscle stiffness and pseudohypertrophy: Hoffmann's syndrome. Am J Med. 1981; 70: 891-894.
13. Mastrpasqua M, Spagna G, Baldini V, et al. Hoffman's syndrome: muscle stiffness, pseudohypertrophy and hypothyroidism. Horm Res. 2003; 59: 105-108.
14. Ozdag MF, Eroglu E, Ulas UH, et al. Early diagnosis and treatment reverse clinical features in Hoffman's syndrome due to hypothyroid myopathy: a case report. Acta Neurol Belg. 2005; 105: 212-213.
15. Madariaga MG. Polymyositis-like syndrome in hypothyroidism: rewiew of cases reported over the past twenty-five years. Thyroid. 2002; 12: 331-336.
16. Ciompi ML, Zuccotti M, Bazzichi L, et al. Polymyositis-like syndrome in hypothyroidism: report of two cases. Thyroid. 1994; 6: 33-36.
17. Tsai WP, Liou LB, Chu CC, et al. Hypothyroid myopathy: a case report. J Microbiol Immunol Infect. 1999; 32: 133-136.
18. Beyer IW, Karmali R, Demeester-Mirkine N, et al. Serum creatine kinase levels in overt and subclinical hypothyroidism. Thyroid. 1998; 8: 1029-1031.
19. Tokinaga K, Oeda T, Suzuki Y, et al. HMG-CoA reductase inhibitors (statins) might causa high elevations of creatine phosphokinase (CK) in patient with unnoticed hypothyroidism. Endocr J. 2006; 53: 401-405.